Media.Player

Ethyl Pyruvate: A Novel Treatment for Inflammation

Detailed Technology Description

None

*Abstract

This patented use of a pyruvate composition treats inflammation by inhibiting the release of TNF, IL1, and HMGB1. In a mouse model, ethyl pyruvate specifically prevents the release of TNF and HMGB1 resulting in enhanced survival from sepsis and septic shock. When ethyl pyruvate was administered 24 hours after sepsis started, it still significantly increased the survival of treated mice. Thus, ethyl pyruvate is effective in treating inflammation; even when administered well after the inflammatory process has started. The conditions treatable by the method of the invention include:1) local and systemic inflammation2) inflammatory bowel disease (Crohn's disease and ulcerative colitis)3) rheumatoid arthritis4) asthma (including status asthmaticus)5) sepsis and septic shock6) inflammatory skin conditions (psoriasis and eczema) Advantages:1) Ethyl pyruvate is non-toxic and well tolerated in humans2) Wide therapeutic window for safe and easy dosing.3) Stable compound4) May be administered via various convenient routes (oral, nasal, venous, muscular, etc) Stage of Development* Animal data is available for ethyl pyruvate as a treatment of inflammation.

*Principal Investigator

Name: Mitchell Fink, Professor

Department: Med-Critical Care Medicine

Name: Kevin Tracey, Head, Cnt. for Patient Oriented Rsch

Department:

Name: Luis Ulloa, Research Associate

Department:

Country/Region

USA